Pneumococcal 21-valent Conjugate Vaccine (Merck Sharp & Dohme)
- Generic Name
- Pneumococcal 21-valent Conjugate Vaccine (Merck Sharp & Dohme)
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 882
- Registration Number
- NCT06177912
- Locations
- 🇨🇦
Premier Clinical Trial Network ( Site 0008), Hamilton, Ontario, Canada
🇺🇸Central Research Associates ( Site 0145), Birmingham, Alabama, United States
🇺🇸Velocity Clinical Research, Phoenix ( Site 0122), Phoenix, Arizona, United States
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
- Conditions
- Pneumococcal Infection
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 518
- Registration Number
- NCT05696080
- Locations
- 🇨🇱
Centro de Investigación del Maule-Centro de Investigación 2 ( Site 1010), Talca, Maule, Chile
🇨🇦Clinique de médecine Urbaine du Quartier Latin ( Site 0111), Montreal, Quebec, Canada
🇺🇸Mid Hudson Medical Research ( Site 0008), New Windsor, New York, United States
Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT05633992
- Locations
- 🇯🇵
PS Clinic ( Site 1002), Fukuoka, Japan
🇯🇵Medical Corporation Shinanokai Shinanozaka Clinic ( Site 1006), Shinjuku-ku, Tokyo, Japan
🇯🇵Heishinkai Medical Group ToCROM Clinic ( Site 1004), Shinjuku-ku, Tokyo, Japan
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1484
- Registration Number
- NCT05569954
- Locations
- 🇩🇪
Universitaetsklinikum Hamburg-Eppendorf-Infektiologie ( Site 0901), Hamburg, Germany
🇰🇷Asan Medical Center ( Site 1809), Seoul, Korea, Republic of
🇰🇷Ewha Womans University Mokdong Hospital-Infectious Diseases ( Site 1805), Seoul, Korea, Republic of
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1080
- Registration Number
- NCT05526716
- Locations
- 🇺🇸
Optimal Research ( Site 0008), Melbourne, Florida, United States
🇺🇸Holston Medical Group-Clinical Research ( Site 0009), Kingsport, Tennessee, United States
🇺🇸Triple O Research Institute, P.A ( Site 0054), West Palm Beach, Florida, United States
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2162
- Registration Number
- NCT05464420
- Locations
- 🇺🇸
L&C Professional Medical Research Institute ( Site 0012), Miami, Florida, United States
🇺🇸Desert Clinical Research/ CCT Research ( Site 0019), Mesa, Arizona, United States
🇺🇸Valley Clinical Trials, Inc. ( Site 0023), Northridge, California, United States
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2663
- Registration Number
- NCT05425732
- Locations
- 🇺🇸
Baptist Health Center For Clinical Research ( Site 0019), Little Rock, Arkansas, United States
🇺🇸Millennium Clinical Trials ( Site 0013), Simi Valley, California, United States
🇺🇸Alliance for Multispecialty Research, LLC ( Site 0015), Coral Gables, Florida, United States
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 717
- Registration Number
- NCT05420961
- Locations
- 🇮🇱
Maccabi Health Services - Holon ( Site 0305), Holon, Israel
🇮🇱Maccabi Healthcare Services ( Site 0306), Jerusalem, Israel
🇮🇱Meir Medical Center ( Site 0301), Kfar Saba, Israel
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
- Conditions
- Pneumococcal Disease
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT05393037
- Locations
- 🇨🇱
Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0107), Santiago, Region M. De Santiago, Chile
🇿🇦Be Part Yoluntu Centre ( Site 0902), Paarl, Western Cape, South Africa
🇿🇦Josha Research ( Site 0900), Bloemfontein, Free State, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.